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OPTIMIZATION OF NONAMBULANT MASS CASUALTY DECONTAMINATION
PROTOCOLS AS PART OF AN INITIAL OR SPECIALIST OPERATIONAL RESPONSE
TO CHEMICAL INCIDENTS
Robert P. Chilcott, MSc, PhD, Hannah Mitchell, BSc(Hons), MSc, Hazem Matar, MSc, PhD
ABSTRACT
Objective: The UK’s Initial Operational Response (IOR) is a
new process for improving the survival of multiple casual-
ties following a chemical, biological, radiological or nuclear
incident. Whilst the introduction of IOR represents a patient-
focused response for ambulant casualties, there is currently
no provision for disrobe and dry decontamination of non-
ambulant casualties. Moreover, the current specialist oper-
ational response (SOR) protocol for nonambulant casualty
decontamination (also referred to as “clinical decontamina-
tion”) has not been subject to rigorous evaluation or devel-
opment. Therefore, the aim of this study was to confirm
the effectiveness of putatively optimized dry (IOR) and
wet (SOR) protocols for nonambulant decontamination in
human volunteers. Methods: Dry and wet decontamina-
tion protocols were objectively evaluated using human vol-
unteers. Decontamination effectiveness was quantified by
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liquid chromatography–mass spectrometry analysis of the
recovery of a chemical warfare agent simulant (methylsali-
cylate) from skin and hair of volunteers, with whole-body
fluorescence imaging to quantify the skin distribution of
residual simulant. Results: Both the dry and wet decontam-
ination processes were rapid (3 and 4 min, respectively) and
were effective in removing simulant from the hair and skin
of volunteers, with no observable adverse effects related to
skin surface spreading of contaminant. Conclusions: Fur-
ther studies are required to assess the combined effectiveness
of dry and wet decontamination under more realistic con-
ditions and to develop appropriate operational procedures
that ensure the safety of first responders. Key words: initial
operational response, IOR; specialist/strategic operational
response, SOR; vulnerable population; mass casualty; decon-
tamination; dry decontamination; wet decontamination
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INTRODUCTION
United Kingdom policy and guidelines for manag-
ing chemical, biological, radiological, and nuclear
(CBRN) incidents have previously utilized a generic
approach (“Model Response”) for the management of
multiple, contaminated individuals that encapsulates
an “all-hazards” incident management strategy (1).
Corresponding studies (2) indicated that the Model
Response tends to focus on process rather than casual-
ties and so recommendationsweremade for new emer-
gency working practices, which became known as the
Initial Operational Response (IOR) and Specialist (or
Strategic) Operational Response (SOR) (3). Essentially,
the IOR introduces the disrobe and ad hoc dry decon-
tamination process at the earliest opportunity, whereas
the SOR relies on the deployment of specialist, mobile
shower units.
A significant objective of the IOR is to complete dis-
robe and decontamination procedures as soon as prac-
tically possible. The most pragmatic option is to use
any readily available (nonproprietary) absorbentmate-
rial to treat exposure to noncaustic liquids, such as
chemical warfare agents and toxic industrial chemicals
(4). Recent work has identified a number of such mate-
rials (5,6). However, while the IOR represents a sub-
stantial improvement in the initial clinicalmanagement
of ambulant casualties, there is currently no compara-
ble protocol for nonambulant patients.
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The SOR is a well-defined plan that originates from
the UK’s Model Response and involves the deploy-
ment of specialist resources, such as mass decontam-
ination units (MDUs). While the MDU showering pro-
tocol for ambulant casualties has been well defined
and evaluated (4,7-9), the nonambulant equivalent
(“clinical decontamination”) has not been subjected to
rigorous testing. Consequently, there is currently no
evidence-based guidance for clinical decontamination.
Here we report the outcomes of 2 human volunteer
studies that evaluated putatively optimized dry (IOR)
andwet (SOR) disrobe and decontamination protocols.
The studies were performed using a relevant chemical
warfare agent simulant (methylsalicylate) containing a
fluorescent dye (curcumin).
MATERIALS AND METHODS
Chemicals
Methylsalicylate (99%) and curcumin (98 +
%, a mixture of dimethoxycurcumin and bis-
dimethoxycurcumin) were purchased from Acros
Organics, UK. The simulant dosing solution (“CMX”)
was prepared on the day of each experiment by gradu-
ally adding 250mg curcumin to 25mLmethylsalicylate
(giving a final curcumin concentration of 10 mg mL−1)
in a lightproof glass container. The mixture was then
sonicated (Nickel Electro Ltd. model SW3H, Fisher
Scientific, UK) for 15 min under lightproof conditions
and stored at room temperature for a maximum of 1 h
before use.
Isopropyl alcohol (high-performance liquid chro-
matography [HPLC] grade), acetonitrile (HPLCgrade),
methanol (HPLC grade), and glacial acetic acid (HPLC
grade) were purchased from Scientific Laboratory Sup-
plies Ltd., Nottinghamshire, UK. Ultra-pure water
(>18.2 M) for LC analysis was filtered from the
municipal supply via a MilliQ Integral 3 (Millipore,
MA, USA).
Volunteers were provided with plain black
swimwear (bikinis for female volunteers, swimming
briefs for males) and plain black unisex outer gar-
ments (100% cotton long-sleeved t-shirts and leisure
trousers), all purchased from Primark, Hampshire,
UK.
Protocol for Evaluation of Disrobe and Dry
Decontamination Protocol (Study 1)
Ethical approval was granted by an Independent
Research Ethics Committee (protocol ITX-IERC-0117A)
and the study was performed in compliance with the
International Conference on Harmonization (ICH) Tri-
partite Guidelines on Good Clinical Practice (GCP).
The study was listed with the International Stan-
dard Randomised Controlled Trial Number Register
(reference ISRCTN12832762). Following completion of
a medical questionnaire to exclude those with rele-
vant pre-existing conditions, a total of 16 volunteers
(8 females and 8 males, average age 33.8 years, range
19 to 59 years) were enrolled and provided informed
consent to participate in the study. Each volunteer
was instructed not to apply any topical formulations
(creams, lotions, sprays, etc.) for at least 24 h prior to
participating in the study. Volunteers were randomly
allocated to treatment groups using an on-line (pseudo-
random) treatment allocator (10). Treatment groups
comprised individuals who were dosed but not decon-
taminated (“control”) and those who were dosed and
subsequently treated with Blue RollTM (“decontami-
nated”). Blue Roll is an absorbent paper material used
for domestic and industrial cleaning and is readily
available to emergency responders.
Following informed consent, each volunteer was
asked to change into the swimwear and outer gar-
ments provided prior to the acquisition of initial
(baseline) images in a bespoke photographic booth.
The volunteer was then escorted to a dosing room,
where a research team member applied 10 µL droplets
of CMX dosing solution to 12 areas of the hair or skin
surfaces and 100 µL droplets of CMX to the surface of
6 clothed sites (Figure 1). The droplets were applied
in both instances using a calibrated, positive displace-
ment pipette. Asecond set of imageswas then acquired
immediately prior to the volunteer entering the disrobe
and decontamination area.
Where applicable, the disrobe and dry decontamina-
tion processwas performed by 3decontamination team
members (DTMs) as follows (Figure 2):
1. Each volunteer was asked to lie on a stretcher
lined with Blue Roll (Wypall, Tork) and to remain
flaccid and unresponsive. Decontamination Team
CMX Contaminaon Sites
= 10 μL
FIGURE 1. Location of chemical warfare agent simulant (CMX)
droplets applied to the clothing, skin and hair of volunteers in the
disrobe and dry decontamination study. The total applied dose of
CMX was 0.72 mL (842 mg).
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A B C D 
E F G H 
FIGURE 2. Representative photographs demonstrating the various stages of the nonambulant disrobe and dry decontamination process.
A = disrobe; B = prioritisation of potentially exposed skin surfaces (hair, face, arms, hands); C = change of Blue Roll and decontamination
of previously clothed skin surfaces; D = body roll of casualty into recovery position on second spine board; E = prioritisation of potentially
exposed skin surfaces (hair, face, arms, hands); F = cleaning of original spine board and replacement of Blue Roll; G = body roll of casualty back
to supine position on original (clean) spine board; H = completion of process – casualty ready for evacuation.
Member 1 (DTM1) supported the head and neck,
using a strip of Blue Roll placed under the volun-
teer’s head.
2. The front of the volunteer’s clothing was cut using
trauma shears (Tuff Cut, RelianceMedical, UK) and
peeled away (Figure 2A). During this time, DTM1
started to blot the hair with Blue Roll.
3. The DTM to the left of the casualty (DTM2) started
blotting accessible areas of the lower limbs, while
DTM3 (to the right of the casualty) blotted the
accessible areas of the upper body (Figure 2B). Both
DTM2 and DTM3 prioritized the areas of skin that
had not been clothed (i.e., feet, hands, and face),
particularly if liquid contaminant was visible on
the skin surface.
4. Following a change of Blue Roll, Team Members
progressed from blotting to rubbing the skin sur-
faces (Figure 2C), after which the volunteer was
carefully rolled to their left on to a clean stretcher
(which was covered with fresh Blue Roll) and
placed into the recovery position. At this and all
other times, DTM1 was using the Blue Roll to sup-
port the head and neck to prevent direct contact
with the hair (Figure 2D).
5. With the volunteer lying in the recovery position
(Figure 2E), step 3 was repeated with fresh Blue
Roll.
6. The original stretcher was wiped down with the
existing Blue Roll (by DTM3) to remove any overt
contamination. The contaminated Blue Roll was
then replaced with fresh material (Figure 2F).
7. The volunteer was then rolled back on to the orig-
inal stretcher, with care to support the head and
neck (Figure 2G).
8. After being placed supine (Figure 2H), the vol-
unteer was instructed that the decontamination
process was completed and was escorted to the
photographic booth for a final photograph.
9. Finally, the volunteer was escorted to a sampling
room for skin and hair surface swabbing.
Each of the aforementioned steps was timed accord-
ing to a predefined protocol, with DTM1 instructing
DTM2 and DTM3 to proceed through each step
(Table 1 ). The whole process took exactly 3 min. Vol-
unteers in the control group were also subjected to the
disrobe procedure and rolled between the stretchers
(according to the timed protocol) but did not undergo
dry decontamination with the Blue Roll.
The swatches of Blue Roll used in the study (for
decontamination of the casualty and lining/cleaning
of the stretchers) were individually weighed, placed
into glass jars and immersed in 300 mL isopropanol
(IPA). All samples were subsequently stored in light-
proof boxes at room temperature (21°C) for up to 3
weeks.
At the end of the study, thewhite Tyvek suitsworn by
the DTMs were imaged to identify any areas of cumu-
lative cross-contamination from the volunteers.
Protocol for Evaluation of Wet
Decontamination Protocol (Study 2)
Ethical approval was granted by an Independent
Research Ethics Committee (protocol ITX-IERC-0217A)
and the study was performed in compliance with the
International Conference on Harmonization (ICH) Tri-
partite Guidelines on Good Clinical Practice (GCP).
The study was listed with the International Stan-
dard Randomised Controlled Trial Number Register
(reference ISRCTN61073828). Following completion of
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Table 1. Summary of disrobe and dry decontamination protocol
Main Tasks
Time (min:sec) DTM1 (head) DTM2 DTM 3
0–1:50 Check airway. Support head
and neck.
Disrobe.
Perform hair
decontamination.
Decontaminate, with initial focus on potentially exposed areas of skin followed by all
other skin surfaces.
1:50 Verbal command to prepare
for body roll.
Finish current decontamination activity and prepare casualty for recovery position.
2:00 Verbal command to perform
body roll.
Roll casualty into recovery position on second stretcher.
Check airway. Support head
and neck. Continue hair
decontamination.
Decontaminate, with initial focus on potentially exposed areas of skin followed by all
other skin surfaces.
2:40 Verbal command to prepare
for body roll.
Continue decontamination. Prepare first stretcher (clean and fresh
Blue Roll).
3:00 Verbal command to perform
body roll.
Roll casualty back to supine position on first stretcher.
Tasks were performed by 3 decontamination team members (DTMs).
a medical questionnaire to exclude those with rele-
vant pre-existing conditions, a total of 18 volunteers
(9 females and 9 males, average age 34.1 years, range
19 to 59 years) were enrolled and provided informed
consent to participate in the study. Each volunteer
was instructed not to apply any topical formulations
(creams, lotions, sprays, etc.) for at least 24 h prior to
participating in the study. Volunteers were randomly
allocated to treatment groups using an on-line (pseudo-
random) treatment allocator (10). Treatment groups
comprised a control (no decontamination) and a decon-
tamination group.
Following informed consent, each volunteer
changed into the provided swimwear before acqui-
sition of a baseline image. The volunteer was
then escorted to a dosing room where a research
team member applied 10 µL droplets of a cur-
cumin/methylsalicylate mixture (CMX) to 16 areas
of the hair or skin surfaces (Figure 3) using a cali-
brated, positive displacement pipette. The volunteer
was then escorted to a photographic booth for a second
picture, immediately prior to entering a standard NHS
clinical decontamination unit (MD16 and MD36 sub-
sections and associated ancillary equipment) kindly
provided by NARU (Winterbourne Gunner, Wiltshire,
UK). Water was delivered to the decontamination
unit directly from the local municipal supply via a
heater (Hughes Portaheater 75) at a temperature of
32–40°C. The flow rate of water at each spray nozzle
was calculated (by the time taken to fill a 1 L bottle) as
4.5 L min−1.
Each volunteer lay down on a stretcher mounted on
a roller-bed (Hughes Safety Showers Ltd.) within the
decontamination unit and was instructed to remain
flaccid and unresponsive.
The decontamination team comprised 4 trained
research staff. Each team member wore a standard
NHS powered respirator protective suit (PRPS), kindly
provided by NARU (Winterbourne Gunner, Wiltshire,
UK) when performing casualty decontamination. Four
clean, absorbent cellulose sponges (“Tesco Sponge
Wipes”) were used for the decontamination of each
volunteer.
Clinical decontamination was performed according
to a 4-min protocol (developed during a previous,
unpublished study). Briefly, an initial (30 s) rinse of
anterior skin and hair surfaces was followed by a
1.5 min wash with sponges (no soap). Following a
partial (90°) roll of the volunteer on to his/her right
side, the process was repeated (30 s rinse, 1.5 min
wash), after which the stretcher was washed before the
volunteer was returned to the supine position. After
dismounting from the stretcher, the volunteer was
CMX Contaminaon Sites
= 10 μL
= 100 μL
FIGURE 3. Location of chemical warfare agent simulant (CMX)
droplets applied to the skin and hair of volunteers in the wet decon-
tamination study. The total applied dose of CMX was 0.16 mL
(187 mg).
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handed a disposable towel (Waffle White Body Towel,
Scrummi, Kent, UK) and instructed to dry for 30 s. Each
of the used towels was weighed and placed into jars
containing IPA (1 L). Immediately after toweling, the
volunteers were escorted to the photographic booth
for a final set of images. The volunteer was then taken
to a sampling room, where each of the dosed sites was
swabbed as described in the following sections.
Participants in the control group underwent the
same procedures (image acquisition, dosing, place-
ment/movement on stretcher in decontamination unit,
and swabbing) but were not subject to the decontami-
nation and toweling stages.
At the end of the study, each DTMwas imaged in the
photographic boothwhilst wearing their PRPS in order
to identify any areas of cumulative cross contamination
from the volunteers.
Hair and Skin Surface Swabbing
Swabs were taken from the surface of exposed skin
and hair surfaces (Figures 1 and 3) of all volunteers to
quantify the recovery of the simulant. To reduce sam-
pling error, swabbing was consistently performed by
the same 2 members of the research team. The swab-
bing process was performed at each site by the serial
application of 3 Q-tipsTM (Unilever, USA) within a cir-
cular (2.5 cm diameter) orifice of a single-use, plas-
tic template placed over the sampling area. The first
Q-tip was applied dry, the second was pre-wetted
with IPA and the third was used dry. Each Q-tip was
applied to the hair or skin surface using light pres-
sure with a circular swabbing motion. After use, the
3 Q-tips were placed into pre-weighed 20 mL vials,
which were re-weighed prior to the addition of IPA
(5 mL). Samples were subsequently stored at room
temperature (21°C) within lightproof boxes for up to
4 weeks.
Sample Preparation
Skin and hair swab samples were vortexed and soni-
cated for 30 s prior to withdrawal of a 1 mL aliquot,
whichwas filtered through a 0.2 µmfilter (13mmOTFE
filter, Chromacol Ltd, Hertfordshire, UK) and trans-
ferred into a 2 mL glass chromatography vial (KRSS,
UK).
Towels and Blue Roll samples were removed from
their storage jars and wrung using a 3.5 L stainless
steel fruit press (AlcoFermBrew, Poland) to extract
any absorbed IPA. The press was thoroughly cleaned
between samples to prevent cross-contamination. The
resulting effluent was transferred back to the original
sample jar, after which an aliquot (1 mL) was filtered
through a 0.2-µm filter and placed into a 2-mL chro-
matography vial.
Fresh sets of calibration and matrix standards (cur-
cumin: 0.001–10 µgmL−1; methylsalicylate: 0.2–1180 µg
mL−1) were prepared for each batch of Q-tip, Blue Roll
and towel samples.
Sample Analysis
All samples were analyzed by liquid chromatography–
diode array detector–mass spectrometry (LC–DAD–
MS). Chromatography was performed using an Agi-
lent 1100 LC system, which consisted of a quaternary
pump, an autosampler, a column oven, and a diode
array detector. The column (Modus C18, 5 µm, 150 ×
2.1 mm; Chromatography Direct, Cheshire, UK) was
maintained at a temperature of 30°C. Themobile phase
was a mixture of ultra-pure water adjusted to pH 3
with acetic acid (60%) and acetonitrile (40%). Methanol
water (50:50) was used as a washing solution and the
needle was washed pre- and postsampling. The injec-
tion volume was 2 µL, with a run time of 10 min at a
flow rate of 0.4mLmin−1. The diode array detectorwas
set to monitor 303 nm (methylsalicylate) and 420 nm
(curcumin) wavelengths. Fresh samples for quality
control were prepared prior to each run by diluting
freshly prepared stock solutions to 1.18, 177 and 826 µg
mL−1. All chromatograms were analyzed and quanti-
fied using proprietary software (Chromeleon v7.2).
Image Acquisition and Analysis
Whole-body fluorescent images were acquired with a
Canon EOS 700D digital camera (exposure time 2 s,
aperture f/4.5, focal length 10 mm) in a light-proof
booth of dimensions 3 m (h) × 2 m (w) × 2 m (d).
An array of 6 × 1200 mm length LED lighting tubes
(Arcadia T8, LED Marine Blue, Arcadia Ltd., Surrey,
UK)was positioned horizontally in front of the camera.
Volunteers were asked to stand 1.5 m from the camera
with the aid of a floor-mounted jig to ensure consis-
tent positioningwhen facing towards or away from the
camera.
The area and intensity of residual simulant (CMX) on
skin and hair surfaces was quantified by image analy-
sis of the baseline, post-dose andpost-decontamination
photographs of each volunteer. The resulting images
were analyzed by one research team member using
National Institute of Health open-source software (11).
Briefly, each baseline image was subtracted from the
corresponding post-decontamination image to reduce
or eliminate background noise. This produced a sin-
gle “clean” image that was subsequently saved as a
separate JPEG file. Each clean image was then sub-
jected to spatial calibration by reference to a grid of
known dimensions within the photographic booth.
Image thresholds were adjusted manually to enable
detection of residual CMX. Areas of the body were
delineated into discreet zones to account for contam-
inant spreading (Figure 4).
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Zone 1
Zone 2
Zone 3
Zone 4 Zone 5
Zone 6
Zone 7
Zone 8 Zone 9
FIGURE 4. Schematic representation of the image analysis zones.
Data and Statistical Analysis
The efficacy of decontamination was calculated from
Equation 1:
%E = 100 −
(
Qd
Qc
× 100
)
(1)
where Q is the quantity of methylsalicylate recovered
from control (c) or decontaminated (d) areas. Statisti-
cal analysis was performed using proprietary software
(GraphPad InStat, version 7.0b).
RESULTS
Statistical analysis (D’Agostino & Pearson) indicated
that the quantities of methylsalicylate recovered from
skin, hair, Blue Roll and towel matrices were non-
parametric. A Kruskal–Wallis test of the skin and
hair recoveries between different anatomical sites of
(untreated) controls (when grouped by unclothed or
clothed sites) indicated that the variation between dif-
ferent anatomical sites was significantly greater than
could be attributed to chance alone (p < 0.0007).
Thus, a standard nonparametric analysis of vari-
ance (ANOVA) with multiple comparisons post-test,
to identify treatment-related effects between different
anatomical sites with (Bonferroni) correction for multi-
ple comparisons, was not deemed appropriate. Conse-
quently, treatment-related effects within each anatomi-
cal site were investigated using a nonpaired, single-tail
Mann–Whitney U-test. The single-tail test was deemed
appropriate as there could only be a decrease in the
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FIGURE 5. Recovery of methylsalicylate from different anatomical locations of volunteers in control ( ) or disrobe and dry decontamination
treatment groups ( ). A & B = unclothed skin (10 µL droplets); C & D = clothed skin (100 µL droplets). Values expressed as mean ± standard
error of the mean (SEM) (n = 8 per treatment group). The asterisk indicates that recovery of methylsalicylate at that anatomical site differs
significantly (p < 0.05) between control and decontaminated treatment groups. Actual p-values are presented in Table 2.
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Table 2. Summary of statistical differences in the recovery
of methylsalicylate between controls (untreated) and dry
(IOR) or wet (SOR) decontamination treatment groups,
derived from nonpaired, single-tail Mann–Whitney U-test
Anatomical Location DRY (IOR) WET (SOR)
Left cheek p = 0.0024 p < 0.0001
Right cheek p < 0.0001 p < 0.0001
Front neck p = 0.0005 p < 0.0001
Back neck p = 0.0249 p = 0.0001
Left palm p = 0.0003 p < 0.0001
Right palm p = 0.0003 NM
Left foot p = 0.0010 p < 0.0001
Right foot p = 0.0007 p < 0.0001
Left hand p = 0.0016 NM
Right hand p = 0.0088 p < 0.0001
Mid-torso, front
∗
p = 0.0758 p < 0.0001
Mid-torso, back
∗
p = 0.0350 p < 0.0001
Right elbow (front)
∗
p = 0.0464 p < 0.0001
Left elbow (back)
∗
p = 0.1524 p = 0.0006
Left shin
∗
p = 0.1615 p < 0.0001
Right calf
∗
p = 0.4282 p < 0.0001
Top head
†
p = 0.1613 p = 0.0070
Back head
†
p = 0.3598 p = 0.0050
NM, not measured.
∗These skin sites were initially clothed.
†See discussion; study design.
recovery of methylsalicylate following decontamina-
tion.
Skin and Hair Recoveries of
Methylsalicylate
Dry Decontamination
The average amounts of methylsalicylate recovered
from control (untreated) skin sites were consistently
greater than those from decontaminated sites for both
unclothed and clothed skin (Figure 5). There was con-
siderable variation in the performance of dry decon-
tamination, with the reduction in contamination rang-
ing from 0% (head) to 99.9% (right cheek) of the
control dose recovered. However, a minimum 95%
reduction in skin contamination was observed for the
majority of anatomical locations investigated (12 out
of 15).
Whilst dry decontamination had a significant effect
on the majority of unclothed skin sites (Figure 5A
and B; p < 0.05), the recoveries of methylsalicylate
from areas of skin that had been subject to com-
bined disrobe and dry decontamination were not sig-
nificantly different to those from controls (disrobe
only) at 4 of the 6 anatomical sites (Figure 5C and
D). The recovery of methylsalicylate from all initially
clothed skin sites (i.e., disrobe only or combined dis-
robe and decontamination) was one to 3 orders of mag-
nitude lower than that from unclothed control sites,
despite the clothed sites having received 10 times the
initial dose of methylsalicylate compared to unclothed
skin.
The outcome of the statistical analysis for dry decon-
tamination is presented in Table 2.
Wet Decontamination
Wet decontamination resulted in consistent and sig-
nificant (p < 0.05) reductions in the amounts of
methylsalicylate recovered from all anatomical loca-
tions (Figure 6). Overall, wet decontamination reduced
skin surface contamination by ∼95–100% in compar-
ison with controls. A 99% or greater reduction in the
recovered dose was observed at more than 2 thirds of
the exposed sites (11 out of 16).
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FIGURE 6. Recovery of methylsalicylate (applied as 10 µL droplets)
fromdifferent anatomical locations of volunteers in control ( ) or wet
( ) decontamination treatment groups. Values expressed as mean ±
standard error of the mean (SEM) (n = 9 per treatment group), using
linear (A) or logarithmic (B) axes. The asterisk indicates that recovery
of methylsalicylate differed significantly (p < 0.05) between control
and decontaminated treatment groups at all anatomical sites. Actual
p-values are presented in Table 2.
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FIGURE 7. Percentage efficacy of dry () or wet ( ) decontamination
(combined from all anatomical locations) of volunteers, expressed as
mean of n = 9.
Comparison of Wet and Dry
Decontamination Efficacy
Overall, bothmethods of decontaminationwere consis-
tently effective in removing the simulant from a range
of anatomical locations (Figure 7). The notable outliers
were dry decontamination of the top of the head (scalp
hair) back of head, right calf, and left elbow.
Recoveries of Methylsalicylate from
Auxiliary Materials
The majority of the applied dose of methylsali-
cylate recovered from samples of Blue Roll was
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FIGURE 8. Percentage of applied dose of methylsalicylate (MS)
recovered from blue roll of control ( ) or decontaminated () treat-
ment groups. Each data point represents the mean ± standard error
of the mean (SEM) of n = 8 replicates.
extracted from swatches used for body decontamina-
tion (Figure 8). Less than 10% of the applied dose was
recovered from Blue Roll used on the hair, which was
not significantly different to the corresponding control.
Transfer of methylsalicylate to the stretcher did not dif-
fer significantly between the control and decontami-
nated groups. Negligible amounts of methylsalicylate
(<0.05% applied dose) were recovered from the towel
following clinical decontamination.
The total recoveries of methylsalicylate from all
experimental compartments indicated an unaccounted
fraction of 30–45% of the applied dose (Figure 9), with
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study).
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less than 1% of the applied dose being recovered from
the skin following wet or dry decontamination.
Image Analysis
In general, the area of contaminationwas not adversely
affected by dry decontamination, with no signifi-
cant differences in skin surface spreading within each
anatomical zone (Figures 10A & B). The intensi-
ties of the contaminated skin areas were consistently
(but not significantly) lower for decontaminated sites
(Figures 10C and D). Similarly, the area of contami-
nation following wet decontamination resulted in no
discernible differences between decontaminated and
control groups (Figure 10E and F). The intensity of con-
tamination was found to be significantly lower follow-
ing wet decontamination for zone 1 (face, neck, and
chest).
Overall, the whole body area of skin contami-
nation was significantly lower when clinical (wet)
decontamination was performed (p < 0.01): no
comparable change was observed following dry
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decontamination (Figure 11A). Whole-body fluo-
rescent intensity was significantly reduced by both
wet and dry decontamination protocols (p < 0.01;
Figure 11B).
Additional Measurements
At the conclusion of the wet decontamination study,
whole-body fluorescent images of each DTM were
acquired while they were wearing PRPS: consistent
areas of cross-contamination were observed in the
palm and groin areas (Figure 12). An accumulation of
contaminantwas also observed over the head area (hel-
met) of one DTM.
LIMITATIONS
While the current investigation provides a robust
assessment of dry and wet decontamination proto-
cols, an obvious limitation is that the studies were
performed under controlled environmental conditions
with a single, mid-volatility chemical warfare agent
simulant. It is strongly recommended that further eval-
uation of the decontamination protocols is performed
under more realistic circumstances using simulants
with different physicochemical properties. This would
also allow the investigation of other operational fac-
tors, such as the control of waste dry decontamination
materials, management of disrobed casualties, safety of
dry decontamination personnel, and improved doffing
procedures for emergency responders.
DISCUSSION
While there is a considerable body of evidence to sup-
port current dry (IOR) and wet (SOR) mass casualty
decontamination procedures for ambulant casualties
(4,5,7,12-14), optimization or assessment of procedures
for nonambulant casualties have not been adequately
addressed (15). This present study has established that
a new procedure for nonambulant disrobe and dry
decontamination is relatively effective and can be com-
pleted within 3 min. Moreover, this study has demon-
strated that a revised process for nonambulant clini-
cal wet decontamination can be performed effectively
within 4 min.
The disrobe and dry decontamination protocol eval-
uated in this study was designed to accommodate
the requirements of casualties with potentially severe
injuries and so aspects of good clinical practice were
observed by the inclusion of airway and spinal man-
agement techniques. This involved one DTM being
responsible for supporting the head of each volunteer
with the “triple airway manoeuvre” (16). A second
aspect of the dry decontamination protocol design was
to eliminate direct contact with the casualty and thus
reduce the risk of cross-contamination. Therefore, the
DTM responsible for spine and airway management
used Blue Roll to form an absorbent, physical barrier
around the casualty’s head. This physical management
of volunteers was identical between the 2 treatment
groups. While representing a sound experimental
design, it introduced an experimental artefact: the
head of each control volunteer was in contact with the
Blue Roll and was thus essentially decontaminated.
Accordingly, the recoveries of simulant from the “back
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FIGURE 12. Whole-body fluorescence images of Decontamination TeamMembers acquired at the conclusion of the wet decontamination study.
Upper row= front view; lower row= rear view. Consistent areas of contamination (hands and groin) are identifiedwithin the oval areas. Helmet
contamination was observed in one individual (dotted line oval).
head” area were corresponding low in both treatment
groups and resulted in the apparent (complete) loss
of decontamination effectiveness at that anatomical
location (Table 2).
A feature of the study design was the incorporation
of disrobing at a third of the exposed skin/hair sites to
allow simultaneous investigation of the effects of com-
bined disrobe and decontamination. The percentages
of the applied dose of simulant recovered from dis-
robed (control and decontaminated) sites were 1 to 3
orders of magnitude lower than those from unclothed
control sites. These data confirm the substantial benefit
of disrobing identified in previous studies (14). A syn-
ergistic effect between decontamination and disrobing
was not consistently observed, although this may be
attributable to the effectiveness of disrobing.
Overall, both dry and wet decontamination proto-
cols were significantly effective, although wet decon-
tamination was more consistent and removed a greater
proportion of contaminant at the majority (∼70%) of
exposed anatomical sites (Figure 7). It should be noted
that the wet decontamination protocol is performed
using bespoke, specialist assets. In contrast, dry decon-
tamination is an ad hoc process that provides poten-
tially life-saving “first aid” for chemical contamination
at the earliest opportunity. Dry and wet decontamina-
tion should therefore be considered as complementary
processes.
An operational consideration that needs to be
addressed is the safety of individuals treating non-
ambulant, contaminated casualties. It is imperative to
develop adequate risk assessments that address the
safety of responders performing dry decontamination.
Further work is required to fully define the risk aris-
ing from a range of chemical contaminants. A second
consideration is that distinct patterns of PRPS contam-
ination were observed in this and (unpublished) pre-
ceding studies, suggesting that the decontamination of
PRPS (prior to doffing) should focus on cleaning areas
associated with the groin and hands. It has also been
observed that individuals wearing oversize PRPS fre-
quently reposition their hood (to improve visibility).
This appears to be associated with increased contam-
ination of the head area (for example see Figure 12).
Therefore, it is recommended that future studies of wet
decontamination incorporate measurements of protec-
tive suit contamination.
To summarise, a protocol for disrobe and dry
decontamination of nonambulant casualties has been
developed and assessed: the new protocol is rapid
(3-min duration), generally effective and establishes
key principles for future implementation as part of
the UK’s IOR. However, it must be reiterated that
dry decontamination is an emergency medical coun-
termeasure that should normally be used in con-
junction with subsequent wet (clinical) decontami-
nation. This study also confirmed the reproducibil-
ity, practicality, and effectiveness of a revised wet
decontamination protocol. The dry and wet decon-
tamination protocols should be evaluated in com-
bination under more realistic conditions to confirm
their clinical effectiveness and appropriate operational
12 PREHOSPITAL EMERGENCY CARE 2018 EARLY ONLINE
proceduresmust be developed that ensure the safety of
first responders.
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